BPC-157 in the laboratory: tendon, gut and blood vessels

A peptide born in gastric juice

BPC-157 is a pentadecapeptide (GEPPPGKPADDAGLV, molecular weight 1419)² that corresponds to a partial sequence of body protection compound, a protein discovered in and isolated from human gastric juice⁶. Its most cited chemical feature is stability: the Zagreb group describes it as stable in human gastric juice for more than 24 hours⁹, which is unusual for a peptide and explains why it was studied orally from the start. Its physicochemical properties are summarized on the BPC-157 page. The 2026 regulatory story and the details of the human reports are in BPC-157: from the Rogan podcast to the FDA vote; this article deals with what happens in the laboratory.

Tendon, ligament and muscle

The reference study is Staresinic and colleagues (2003): in rats with a transected Achilles tendon, daily intraperitoneal BPC-157 was associated, versus saline, with higher load to failure and Young's modulus, higher Achilles functional index values, more fibroblasts, reticulin and collagen, and a smaller tendon defect, assessed between days 1 and 14². In culture, the peptide did not stimulate tenocyte growth on its own, but it reversed the inhibition caused by 4-hydroxynonenal, a lipid-peroxidation aldehyde².

The same pattern was described in other structures. In Achilles detachment from the calcaneus, an injury that does not heal spontaneously in the rat, BPC-157 was associated with better function, stiffness and load to failure, more type I collagen and better fiber organization up to day 21; it also reduced the healing impairment induced by methylprednisolone³. In the medial collateral ligament, followed for 90 days, it was associated with better functional, biomechanical and histological healing when given intraperitoneally, topically as a cream and orally in drinking water⁴. In gastrocnemius crush injury there was less hematoma and edema, no contracture and lower creatine kinase and other enzymes⁵.

The mechanism, seen by an independent laboratory

Much of the mechanistic explanation comes from Chang Gung University in Taiwan, a group unrelated to Zagreb. In rat Achilles tendon explants, BPC-157 accelerated fibroblast outgrowth; in the MTT assay it did not directly change proliferation, but it increased cell survival under hydrogen peroxide stress and dose-dependently increased fibroblast migration and spreading, with more F-actin⁶. Phosphorylation of FAK and paxillin, two focal-adhesion proteins, rose with dose while their total amounts were unchanged⁶. In other words, the described effect is not "making tissue grow" but mobilizing and protecting the cells that repair it.

In a 2018 review, the Zagreb group compared BPC-157 with the classic angiogenic growth factors (EGF, FGF, VEGF) and argued that only BPC-157 was consistently effective in all models of acute and chronic gastrointestinal injury, given intraperitoneally, orally or locally, and that with the same regimens it improved tendon, ligament and bone healing⁷. This is the authors' own thesis, but it captures what makes this literature distinctive: a single peptide, with no carrier, with one dose range shared across very different tissues.

Gut: ulcers, fistulas and anastomoses

The digestive tract is BPC-157's original territory. In rats, healing of gastrocutaneous, duodenocutaneous and colocutaneous fistulas has been described, with closure even when treatment began one month after the fistula was created, and in a 4-week short-bowel model it was associated with weight gain and greater villus height and crypt depth¹. A 2020 review extends the list to internal fistulas (colovesical, rectovaginal) and to esophagogastric, jejunoileal, colocolic and other anastomoses⁹.

One example shows how this relates to nitric oxide. In rat esophagogastric anastomosis, a typically lethal model, BPC-157, injected or in drinking water, eliminated mortality over the 4 days of follow-up; the NO-synthase blocker L-NAME worsened the course and BPC-157 cancelled that worsening⁸. The authors interpret the anastomosis as a "disability" of the nitric oxide system that the peptide corrects⁸.

Vessels: VEGFR2 and nitric oxide

The same Taiwanese group studied the vascular component. BPC-157 increased vessel density in the chick chorioallantoic membrane and endothelial tube formation, and in rats with hind-limb ischemia it accelerated blood-flow recovery measured by laser Doppler and increased vessel numbers¹⁰. In human endothelial cells it increased VEGFR2 expression, but not VEGF-A, promoted receptor internalization and activated the VEGFR2-Akt-eNOS pathway; the endocytosis inhibitor dynasore blocked these effects¹⁰.

A second study described concentration-dependent vasodilation in isolated rat aorta, attenuated without endothelium and suppressed by L-NAME or hemoglobin, that is, mediated by nitric oxide; the proposed mechanism is activation of Src and caveolin-1, which releases eNOS from its binding to caveolin¹¹. These independent findings give a coherent molecular basis to what Zagreb observed in tendon and gut: more perfusion and more endothelial signaling in injured tissue.

The oral route and the pharmacokinetic paradox

Oral efficacy in the ligament and anastomosis models⁴⁸ is consistent with the described gastric stability, but it has not been characterized in humans. The only formal pharmacokinetic study, from an independent Chinese group, found in rats and dogs a half-life under 30 minutes, intramuscular bioavailability of 14–19% in rats and 45–51% in dogs, and rapid breakdown into small fragments and amino acids¹². A 2026 pharmaceutical review calls this a pharmacokinetic-pharmacodynamic disconnect: a half-life of minutes versus biological effects lasting hours to days¹³.

Where the evidence ends

The limits are as concrete as the findings. A 2025 systematic review included 36 musculoskeletal studies: 35 preclinical and 1 clinical¹⁴. BPC-157 was tested as PL 14736 in trials for inflammatory bowel disease, described by the Zagreb group as safe¹, but the 2026 review notes that no phase 2 trial has been completed and that clinical data come from fewer than 30 subjects in three uncontrolled pilot studies without standardized pharmaceutical preparations¹³. Most of the animal literature comes from a single group in Zagreb; the Taiwanese and Chinese laboratories provide mechanistic and pharmacokinetic replication, not efficacy trials⁶¹⁰¹².

The pro-angiogenic effect also raises a theoretical question about tumor growth, covered in the article on the FDA and BPC-157. The Zagreb group replies that BPC-157 does not produce corneal neovascularization but opposes it, and describes anti-tumor potential in vivo and in vitro¹⁵; no human data can yet settle the question.